IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by BIT Capital GmbH

Key Points

• BIT Capital GmbH reduced its stake in IDEAYA Biosciences, Inc. by 32.9%, selling 20,957 shares and leaving them with 42,715 shares valued at approximately $700,000.
• Several institutional investors, such as Mariner LLC and PNC Financial Services Group, have increased their holdings in IDEAYA, indicating positive sentiment among large investors.
• Analysts have mixed ratings for IDEAYA, with three rating it as a hold and ten as a buy, while the consensus price target is set at $48.09.

BIT Capital GmbH cut its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 32.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,715 shares of the company's stock after selling 20,957 shares during the period. BIT Capital GmbH's holdings in IDEAYA Biosciences were worth $700,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at about $47,000. CWM LLC lifted its stake in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares in the last quarter. Signaturefd LLC raised its holdings in IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after purchasing an additional 2,271 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of IDEAYA Biosciences by 46.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after buying an additional 2,112 shares in the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

Shares of IDYA traded down $1.03 during mid-day trading on Thursday, hitting $22.60. 240,984 shares of the company were exchanged, compared to its average volume of 1,156,202. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -5.95 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $40.74. The company has a 50 day moving average of $22.37 and a 200-day moving average of $20.38.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The company's quarterly revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.68) earnings per share. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a report on Monday, July 28th. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price on the stock. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price objective for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target for the company in a research report on Thursday, July 10th. Finally, TD Cowen began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating on the stock. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.